Literature DB >> 21592300

Changing patterns of bladder cancer in the USA: evidence of heterogeneous disease.

Yawei Zhang1, Cairong Zhu, Maria Paula Curado, Tongzhang Zheng, Peter Boyle.   

Abstract

OBJECTIVE: To test the hypothesis that bladder cancer is a heterogeneous disease. PATIENTS AND METHODS: We examined the temporal trends of bladder cancer by histological subtype and by disease stage and grade using the National Cancer Institute's Surveillance, Epidemiology, and End Results data collected in 1973-2007.
RESULTS: The age-adjusted incidence rates of bladder cancer showed a slight decrease from 1973 to 2007 (annual percentage change [APC] = -0.4, P < 0.05). Although the age-adjusted incidence rates of non-papillary transitional cell carcinoma decreased by about 53% from 7.9 per 100,000 in 1973 to 3.7 per 100,000 in 2007 (APC = -2.2, P < 0.05), the age-adjusted incidence rates of papillary transitional cell carcinoma increased by about 56% from 6.8 per 100,000 in 1973 to 10.6 per 100,000 in 2007 (APC = 0.5, P < 0.05). Among other rare histological subtypes, except for small cell carcinoma which showed a slightly rising trend, squamous cell carcinoma, adenocarcinoma and others all presented a decreasing trend. Similar patterns were found for different stages (localized, regional and distant), but a dramatic increasing trend of grade IV was found between 1998 and 2007 when a corresponding decreasing trend was shown for grades I, II and III.
CONCLUSION: The results support the hypothesis that bladder cancer is a heterogeneous disease and taking disease heterogeneity into consideration in future epidemiological studies is essential.
© 2011 THE AUTHORS. BJU INTERNATIONAL © 2011 BJU INTERNATIONAL.

Entities:  

Mesh:

Year:  2011        PMID: 21592300      PMCID: PMC3218244          DOI: 10.1111/j.1464-410X.2011.10283.x

Source DB:  PubMed          Journal:  BJU Int        ISSN: 1464-4096            Impact factor:   5.588


  18 in total

1.  State-specific prevalence and trends in adult cigarette smoking--United States, 1998-2007.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2009-03-13       Impact factor: 17.586

Review 2.  Contamination of drinking-water by arsenic in Bangladesh: a public health emergency.

Authors:  A H Smith; E O Lingas; M Rahman
Journal:  Bull World Health Organ       Date:  2000       Impact factor: 9.408

3.  Arsenic concentrations in prediagnostic toenails and the risk of bladder cancer in a cohort study of male smokers.

Authors:  Dominique S Michaud; Margaret E Wright; Kenneth P Cantor; Philip R Taylor; Jarmo Virtamo; Demetrius Albanes
Journal:  Am J Epidemiol       Date:  2004-11-01       Impact factor: 4.897

Review 4.  Non-invasive papillary urothelial neoplasms: the 2004 WHO/ISUP classification system.

Authors:  Hiroshi Miyamoto; Jeremy S Miller; Daniel A Fajardo; Thomas K Lee; George J Netto; Jonathan I Epstein
Journal:  Pathol Int       Date:  2010-01       Impact factor: 2.534

5.  Cancer burden from arsenic in drinking water in Bangladesh.

Authors:  Yu Chen; Habibul Ahsan
Journal:  Am J Public Health       Date:  2004-05       Impact factor: 9.308

6.  Case-control study of bladder cancer and exposure to arsenic in Argentina.

Authors:  Michael N Bates; Omar A Rey; Mary L Biggs; Claudia Hopenhayn; Lee E Moore; David Kalman; Craig Steinmaus; Allan H Smith
Journal:  Am J Epidemiol       Date:  2004-02-15       Impact factor: 4.897

Review 7.  Evidence-based principles of bladder cancer and diet.

Authors:  Jonathan L Silberstein; J Kellogg Parsons
Journal:  Urology       Date:  2009-10-12       Impact factor: 2.649

Review 8.  Arylamine exposures and bladder cancer risk.

Authors:  Mimi C Yu; Paul L Skipper; Steven R Tannenbaum; Kenneth K Chan; Ronald K Ross
Journal:  Mutat Res       Date:  2002-09-30       Impact factor: 2.433

9.  Case-control study of bladder cancer and arsenic in drinking water.

Authors:  M N Bates; A H Smith; K P Cantor
Journal:  Am J Epidemiol       Date:  1995-03-15       Impact factor: 4.897

10.  Trends in incidence rates of tobacco-related cancer, selected areas, SEER Program, United States, 1992-2004.

Authors:  Anthony P Polednak
Journal:  Prev Chronic Dis       Date:  2008-12-15       Impact factor: 2.830

View more
  12 in total

1.  Differential DNA methylation in blood as a mediator of the association between cigarette smoking and bladder cancer risk among postmenopausal women.

Authors:  Kristina M Jordahl; Amanda I Phipps; Timothy W Randolph; Hilary A Tindle; Simin Liu; Lesley F Tinker; Karl T Kelsey; Emily White; Parveen Bhatti
Journal:  Epigenetics       Date:  2019-06-23       Impact factor: 4.528

2.  Opportunistic Disease or Metastatic Lesions: A Rare Finding in a Patient with Bladder Cancer.

Authors:  Michael Simon; Natalie Elkayam; Jonathan Smerling; Michael Marcelin; Stephan Kamholz
Journal:  Curr Urol       Date:  2019-09-10

3.  Genome-Wide DNA Methylation in Prediagnostic Blood and Bladder Cancer Risk in the Women's Health Initiative.

Authors:  Kristina M Jordahl; Timothy W Randolph; Xiaoling Song; Cassandra L Sather; Lesley F Tinker; Amanda I Phipps; Karl T Kelsey; Emily White; Parveen Bhatti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-14       Impact factor: 4.254

Review 4.  Role of oestrogen receptors in bladder cancer development.

Authors:  Iawen Hsu; Spencer Vitkus; Jun Da; Shuyuan Yeh
Journal:  Nat Rev Urol       Date:  2013-04-16       Impact factor: 14.432

5.  A population-based study of incidence and patient survival of small cell carcinoma in the United States, 1992-2010.

Authors:  Graça M Dores; Osama Qubaiah; Ankur Mody; Bassam Ghabach; Susan S Devesa
Journal:  BMC Cancer       Date:  2015-03-27       Impact factor: 4.430

Review 6.  Immunotherapy in urothelial carcinoma: fade or future standard?

Authors:  Johannes Breyer; Maximilian Burger; Wolfgang Otto
Journal:  Transl Androl Urol       Date:  2016-10

7.  A Carcinogen-induced mouse model recapitulates the molecular alterations of human muscle invasive bladder cancer.

Authors:  Damiano Fantini; Alexander P Glaser; Kalen J Rimar; Yiduo Wang; Matthew Schipma; Nobish Varghese; Alfred Rademaker; Amir Behdad; Aparna Yellapa; Yanni Yu; Christie Ching-Lin Sze; Lu Wang; Zibo Zhao; Susan E Crawford; Deqing Hu; Jonathan D Licht; Clayton K Collings; Elizabeth Bartom; Dan Theodorescu; Ali Shilatifard; Joshua J Meeks
Journal:  Oncogene       Date:  2018-01-25       Impact factor: 9.867

8.  Antibody targeting of B7-H4 enhances the immune response in urothelial carcinoma.

Authors:  Joseph R Podojil; Alexander P Glaser; Dylan Baker; Elise T Courtois; Damiano Fantini; Yanni Yu; Valerie Eaton; Santhosh Sivajothi; Mingyi Chiang; Arighno Das; Kimberly A McLaughlin; Paul Robson; Stephen D Miller; Joshua J Meeks
Journal:  Oncoimmunology       Date:  2020-04-16       Impact factor: 8.110

9.  Effect of Phellius linteus water extract on benign prostatic hyperplasia.

Authors:  Yu-Na Kim; Min-Sun Kim; Sung-Sik Chun; Jeong-Hwa Choi
Journal:  Nutr Res Pract       Date:  2013-06-03       Impact factor: 1.926

10.  Benign prostatic hyperplasia is a significant risk factor for bladder cancer in diabetic patients: a population-based cohort study using the National Health Insurance in Taiwan.

Authors:  Chin-Hsiao Tseng
Journal:  BMC Cancer       Date:  2013-01-04       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.